Top

CNS Drugs

Published in:

01-11-2009 | Review Article

Cholinergic Functioning in Stimulant Addiction

Implications for Medications Development

Authors: Dr Mehmet Sofuoglu, Marc Mooney

Published in: CNS Drugs | Issue 11/2009

Abstract

Acetylcholine, the first neurotransmitter discovered, participates in many CNS functions, including sensory and motor processing, sleep, nociception, mood, stress response, attention, arousal, memory, motivation and reward. These diverse cholinergic effects are mediated by nicotinic- and muscarinic-type cholinergic receptors (nAChR and mAChR, respectively). The goal of this review is to synthesize a growing literature that supports the potential role of acetylcholine as a treatment target for stimulant addiction. Acetylcholine interacts with the dopaminergic reward system in the ventral tegmental area, nucleus accumbens and prefrontal cortex. In the ventral tegmental area, both nAChR and mAChR stimulate the dopaminergic system. In the nucleus accumbens, cholinergic interneurons integrate cortical and subcortical information related to reward. In the prefrontal cortex, the cholinergic system contributes to the cognitive aspects of addiction. Preclinical studies support a facilitative role of nicotinic receptor agonists in the development of stimulant addiction. In contrast, nonselective muscarinic receptor agonists seem to have an inhibitory role. In human studies, acetylcholinesterase inhibitors, which increase synaptic acetylcholine levels, have shown promise for the treatment of stimulant addiction. Further studies testing the efficacy of cholinergic medications for stimulant addiction are warranted.

Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropharmacology. 8th ed. Oxford: Oxford University Press, 2003

Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006 Jul; 26(3): 219–33PubMedCrossRef

Gu Q. Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity. Neuroscience 2002; 111(4): 815–35PubMedCrossRef

Lucas-Meunier E, Fossier P, Baux G, et al. Cholinergic modulation of the cortical neuronal network. Pflugers Arch 2003 Apr; 446(1): 17–29PubMed

Perry E, Walker M, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 1999 Jun; 22(6): 273–80PubMedCrossRef

Smythies J, Section I: the cholinergic system. Int Rev Neurobiol 2005; 64: 1–122PubMedCrossRef

Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. Neuropsychopharmacology 2007 Jul; 33(8): 1779–97PubMedCrossRef

Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007; 47: 699–729PubMedCrossRef

Mesulam MM. The cholinergic innervation of the human cerebral cortex. Prog Brain Res 2004; 145: 67–78PubMedCrossRef

10.

Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007 Mar; 12(3): 232–46PubMed

11.

Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 1999 Nov; 49(11): 921–37PubMedCrossRef

12.

Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006 Feb; 9(1): 101–24PubMedCrossRef

13.

Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer’s disease. Curr Pharm Des 2005; 11(26): 3353–61PubMedCrossRef

14.

Caulfield MP, Birdsall NJ. International Union of Pharmacology: XVII, classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998 Jun; 50(2): 279–90PubMed

15.

Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007 Sep; 6(9): 721–33PubMedCrossRef

16.

Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 2008 May; 154(2): 327–42PubMedCrossRef

17.

Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nat Rev Neurosci 2007 Nov; 8(11): 844–58PubMedCrossRef

18.

Lu L, Koya E, Zhai H, et al. Role of ERK in cocaine addiction. Trends Neurosci 2006 Dec; 29(12): 695–703PubMedCrossRef

19.

Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 2004; 44: 423–50PubMedCrossRef

20.

Oki T, Takagi Y, Inagaki S, et al. Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res 2005 Jan 5; 133(1): 6–11PubMedCrossRef

21.

Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008 Feb; 117(2): 232–43PubMedCrossRef

22.

Felder CC, Bymaster FP, Ward J, et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 2000 Nov 16; 43(23): 4333–53PubMedCrossRef

23.

Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004 Sep; 18(12): 1410–2PubMed

24.

Picciotto MR, Corrigall WA. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 2002; 22(9): 3338–41PubMed

25.

Picciotto MR, Zoli M, Lena C, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995 Mar 2; 374(6517): 65–7PubMedCrossRef

26.

Epping-Jordan MP, Watkins SS, Koob GF, et al. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998 May 7; 393(6680): 76–9PubMedCrossRef

27.

Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992 Jun 28; 654: 171–91PubMedCrossRef

28.

Kahlig KM, Binda F, Khoshbouei H, et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 2005 Mar 1; 102(9): 3495–500PubMedCrossRef

29.

Tzschentke TM, Schmidt WJ. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003 Apr; 8(4): 373–82PubMedCrossRef

30.

Di Chiara G, Morelli M, Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/ NMDA interactions. Trends Neurosci 1994 Jun; 17(6): 228–33PubMedCrossRef

31.

Forster GL, Blaha CD. Laterodorsal tegmental stimulation elicits dopamine efflux in the rat nucleus accumbens by activation of acetylcholine and glutamate receptors in the ventral tegmental area. Eur J Neurosci 2000 Oct; 12(10): 3596–604PubMedCrossRef

32.

Woolf NJ, Butcher LL. Cholinergic systems in the rat brain: III, projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res Bull 1986 May; 16(5): 603–37PubMedCrossRef

33.

Barazangi N, Role LW. Nicotine-induced enhancement of glutamatergic and GABAergic synaptic transmission in the mouse amygdala. J Neurophysiol 2001 Jul; 86(1): 463–74PubMed

34.

Calabresi P, Picconi B, Parnetti L, et al. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine-acetylcholine synaptic balance. Lancet Neurol 2006 Nov; 5(11): 974–83PubMedCrossRef

35.

Cragg SJ. Meaningful silences: how dopamine listens to the ACh pause. Trends Neurosci 2006 Mar; 29(3): 125–31PubMedCrossRef

36.

Bertorelli R, Consolo S. D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J Neurochem 1990 Jun; 54(6): 2145–8PubMedCrossRef

37.

Berlanga ML, Olsen CM, Chen V, et al. Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine. Neuroscience 2003; 120(4): 1149–56PubMedCrossRef

38.

Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci 2001; 24: 167–202PubMedCrossRef

39.

Sarter M, Bruno JP, Parikh V, et al. Forebrain dopaminergic-cholinergic interactions, attentional effort, psychostimulant addiction and schizophrenia. EXS 2006; 98: 65–86PubMed

40.

Ersche KD, Clark L, London M, et al. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology 2006; 31(5): 1036–47PubMedCrossRef

41.

Verdejo-Garcia A, Benbrook A, Funderburk F, et al. The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend 2007 Sep 6; 90(1): 2–11PubMedCrossRef

42.

Verdejo-Garcia AJ, Perales JC, Perez-Garcia M. Cognitive impulsivity in cocaine and heroin polysubstance abusers. Addict Behav 2007 May; 32(5): 950–66PubMedCrossRef

43.

Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol 2001; 11(2): 250–7PubMedCrossRef

44.

Jovanovski D, Erb S, Zakzanis KK. Neurocognitive deficits in cocaine users: a quantitative review of the evidence. J Clin Exp Neuropsychol 2005; 27(2): 189–204PubMedCrossRef

45.

Bolla KI, Rothman R, Cadet JL. Dose-related neurobehavioral effects of chronic cocaine use. J Neuropsychiatry Clin Neurosci 1999; 11(3): 361–9PubMed

46.

Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002 Mar 1; 43(3): 181–7PubMedCrossRef

47.

Capriles N, Rodaros D, Sorge RE, et al. A role for the prefrontal cortex in stress- and cocaine-induced reinstatement of cocaine seeking in rats. Psychopharmacology 2003 Jul; 168(1–2): 66–74PubMedCrossRef

48.

Di Pietro NC, Black YD, Kantak KM. Context-dependent prefrontal cortex regulation of cocaine self-administration and reinstatement behaviors in rats. Eur J Neurosci 2006 Dec; 24(11): 3285–98PubMedCrossRef

49.

Fuchs RA, Evans KA, Ledford CC, et al. The role of the dorsomedial prefrontal cortex, basolateral amygdala, and dorsal hippocampus in contextual reinstatement of cocaine seeking in rats. Neuropsychopharmacology 2005 Feb; 30(2): 296–309PubMedCrossRef

50.

Ichikawa J, Chung YC, Li Z, et al. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 2002 Dec 20; 958(1): 176–84PubMedCrossRef

51.

Zmarowski A, Sarter M, Bruno JP. Glutamate receptors in nucleus accumbens mediate regionally selective increases in cortical acetylcholine release. Synapse 2007 Mar; 61(3): 115–23PubMedCrossRef

52.

Ikemoto S, Goeders NE. Intra-medial prefrontal cortex injections of scopolamine increase instrumental responses for cocaine: an intravenous self-administration study in rats. Brain Res Bull 2000 Jan 15; 51(2): 151–8PubMedCrossRef

53.

Mansvelder HD, van Aerde KI, Couey JJ, et al. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl) 2006; 184(3–4): 292–305CrossRef

54.

Hikida T, Kaneko S, Isobe T, et al. Increased sensitivity to cocaine by cholinergic cell ablation in nucleus accumbens. Proc Natl Acad Sci U S A 2001 Nov 6; 98(23): 13351–4PubMedCrossRef

55.

de la Garza R, Johanson CE. Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol Biochem Behav 1982 Dec; 17(6): 1295–9PubMedCrossRef

56.

Hikida T, Kitabatake Y, Pastan I, et al. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. Proc Natl Acad Sci U S A 2003 May 13; 100(10): 6169–73PubMedCrossRef

57.

Andersen MB, Werge T, Fink-Jensen A. The acetylcholinesterase inhibitor galantamine inhibits d-amphetamine-induced psychotic-like behavior in Cebus monkeys. J Pharmacol Exp Ther 2007 Jun; 321(3): 1179–82PubMedCrossRef

58.

Takamatsu Y, Yamanishi Y, Hagino Y, et al. Differential effects of donepezil on methamphetamine and cocaine dependencies. Ann N Y Acad Sci 2006 Aug; 1074: 418–26PubMedCrossRef

59.

Hiranita T, Nawata Y, Sakimura K, et al. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A 2006 May 30; 103(22): 8523–7PubMedCrossRef

60.

Bechtholt AJ, Mark GP. Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats. Psychopharmacology 2002 Jul; 162(2): 178–85PubMedCrossRef

61.

Hansen ST, Mark GP. The nicotinic acetylcholine receptor antagonist mecamylamine prevents escalation of cocaine self-administration in rats with extended daily access. Psychopharmacology 2007 Sep; 194(1): 53–61PubMedCrossRef

62.

Kelly PH, Miller RJ. The interaction of neuroleptic and muscarinic agents with central dopaminergic systems. Br J Pharmacol 1975 May; 54(1): 115–21PubMed

63.

Mark GP, Kinney AE, Grubb MC, et al. Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats. Brain Res 2006 Dec 6; 1123(1): 51–9PubMedCrossRef

64.

Rasmussen T, Sauerberg P, Nielsen EB, et al. Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice. Eur J Pharmacol 2000 Aug 25; 402(3): 241–6PubMedCrossRef

65.

Wilson MC, Schuster CR. Cholinergic influence on intravenous cocaine self-administration by rhesus monkeys. Pharmacol Biochem Behav 1973 Nov–Dec; 1(6): 643–9PubMedCrossRef

66.

Wang JQ, McGinty JF. Muscarinic receptors regulate striatal neuropeptide gene expression in normal and amphetamine-treated rats. Neuroscience 1996 Nov; 75(1): 43–56PubMedCrossRef

67.

Ranaldi R, Woolverton WL. Self-administration of cocaine: scopolamine combinations by rhesus monkeys. Psychopharmacology 2002 Jun; 161(4): 442–8PubMedCrossRef

68.

Gerber DJ, Sotnikova TD, Gainetdinov RR, et al. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 2001 Dec 18; 98(26): 15312–7PubMedCrossRef

69.

Carrigan KA, Dykstra LA. Behavioral effects of morphine and cocaine in M1 muscarinic acetylcholine receptor-deficient mice. Psychopharmacology 2007 May; 191(4): 985–93PubMedCrossRef

70.

Brady AE, Jones CK, Bridges TM, et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther 2008 Dec; 327(3): 941–53PubMedCrossRef

71.

Thomsen M, Woldbye DP, Wortwein G, et al. Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 2005 Sep 7; 25(36): 8141–9PubMedCrossRef

72.

Janowsky DS, el-Yousef MK, Davis JM, et al. Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry 1973 Dec; 130(12): 1370–6PubMed

73.

De La Garza R, Shoptaw S, Newton TF. Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. Int J Neuropsychopharmacol 2008 Sep; 11(6): 729–41

74.

De La Garza 2nd R, Mahoney 3rd JJ, Culbertson C, et al. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav 2008 Apr; 89(2): 200–8CrossRef

75.

Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005 Mar; 100 Suppl. 1: 68–77CrossRef

76.

Kouri EM, Stull M, Lukas SE. Nicotine alters some of cocaine’s subjective effects in the absence of physiological or pharmacokinetic changes. Pharmacol Biochem Behav 2001 May–Jun; 69(1–2): 209–17PubMedCrossRef

77.

Sobel BF, Sigmon SC, Griffiths RR. Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsychopharmacology 2004 May; 29(5): 991–1003PubMedCrossRef

78.

Reid MS, Mickalian JD, Delucchi KL, et al. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology 1999 Mar; 20(3): 297–307PubMedCrossRef

79.

Reid MS, Angrist B, Baker SA, et al. A placebo controlled, double-blind study of mecamylamine treatment for cocaine dependence in patients enrolled in an opiate replacement program. Subst Abus 2005 Jun; 26(2): 5–14PubMedCrossRef

80.

Penetar DM, Looby AR, Su Z, et al. Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers. Hum Psychopharmacol 2006 Dec; 21(8): 549–59PubMedCrossRef

81.

Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006; (1): CD005593

82.

Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatr 2002; 14Suppl. 1: 93–126PubMedCrossRef

83.

Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004 Oct; 50(4): 433–40PubMedCrossRef

84.

Camicioli R, Gauthier S. Clinical trials in Parkinson’s disease dementia and dementia with Lewy bodies. Can J Neurol Sci 2007 Mar; 34Suppl. 1: S109–17PubMed

85.

Ochoa EL, Clark E. Galantamine may improve attention and speech in schizophrenia. Hum Psychopharmacol 2006 Mar; 21(2): 127–8PubMedCrossRef

86.

Khateb A, Ammann J, Annoni JM, et al. Cognition-enhancing effects of donepezil in traumatic brain injury. Eur Neurol 2005; 54(1): 39–45PubMedCrossRef

87.

Marco-Contelles J, do Carmo Carreiras M, Rodriguez C, et al. Synthesis and pharmacology of galantamine. Chem Rev 2006; 106(1): 116–33PubMedCrossRef

88.

Schilstrom B, Ivanov VB, Wiker C, et al. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007; 32(1): 43–53PubMedCrossRef

89.

Diehl A, Nakovics H, Croissant B, et al. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther 2006 Dec; 44(12): 614–22PubMed

90.

Aharonovich E, Hasin DS, Brooks AC, et al. Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend 2006; 81(3): 313–22PubMedCrossRef

91.

Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depend 2003; 71(2): 207–11PubMedCrossRef

92.

Streeter CC, Terhune DB, Whitfield TH, et al. Performance on the stroop predicts treatment compliance in cocaine-dependent individuals. Neuropsychopharmacology 2008 Mar; 33(4): 827–36PubMedCrossRef

93.

Etter JF, Lukas RJ, Benowitz NL, et al. Cytisine for smoking cessation: a research agenda. Drug Alcohol Depend 2008 Jan 1; 92(1–3): 3–8PubMedCrossRef

94.

Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48(10): 3474–7PubMedCrossRef

95.

Dunbar G, Boeijinga PH, Demazieres A, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 2007 May; 191(4): 919–29PubMedCrossRef

96.

CHANTIX™ oral tablets [product information]. New York: Pfizer Labs, 2008

97.

Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psycho-stimulant abuse. Biochem Pharmacol 2002 Jan 15; 63(2): 89–98PubMedCrossRef

98.

Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 2000; (2): CD000124

99.

Wilhelm CJ, Johnson RA, Eshleman AJ, et al. Lobeline effects on tonic and methamphetamine-induced dopamine release. Biochem Pharmacol 2008 Mar 15; 75(6): 1411–5PubMedCrossRef

100.

Eyerman DJ, Yamamoto BK. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 2005 Jan; 312(1): 160–9PubMedCrossRef

101.

Vocci FJ, Appel NM. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007 Apr; 102 Suppl. 1: 96–106CrossRef

102.

Chan WY, McKinzie DL, Bose S, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A 2008 Aug 5; 105(31): 10978–83PubMedCrossRef

103.

May LT, Avlani VA, Langmead CJ, et al. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 2007 Aug; 72(2): 463–76PubMedCrossRef

104.

Surig U, Gaal K, Kostenis E, et al. Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds. Arch Pharm (Weinheim) 2006 Apr; 339(4): 207–12CrossRef

105.

Valant C, Gregory KJ, Hall NE, et al. A novel mechanism of G protein-coupled receptor functional selectivity: muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 2008 Oct 24; 283(43): 29312–21PubMedCrossRef

Title: Cholinergic Functioning in Stimulant Addiction
Implications for Medications Development
Authors: Dr Mehmet Sofuoglu
Marc Mooney
Publication date: 01-11-2009
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 11/2009
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/11310920-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cholinergic Functioning in Stimulant Addiction

Implications for Medications Development

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2009

Of Mice and Men

Epidemiology and Management of Anxiety in Patients with Bipolar Disorder

Aggressive Behaviour in Adults with Intellectual Disability

Experience with Intravenous Levetiracetam in Status Epilepticus

Adjustment Disorder

Visual Field Loss in Patients with Refractory Partial Epilepsy Treated with Vigabatrin